Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

KOKON: A Germany-Wide Collaborative Research Project to Identify Needs, Provide Information, Foster Communication and Support Decision-Making about Complementary and Alternative Medicine in Oncology.

Güthlin C, Bartsch HH, Joos S, Längler A, Lampert C, Ritter C, Schildmann J, Weis J, Wilhelm M, Witt CM, Horneber M.

Complement Med Res. 2019 Nov 13:1-7. doi: 10.1159/000502945. [Epub ahead of print] Review.

PMID:
31722354
2.

The cerebellum is involved in processing of predictions and prediction errors in a fear conditioning paradigm.

Ernst TM, Brol AE, Gratz M, Ritter C, Bingel U, Schlamann M, Maderwald S, Quick HH, Merz CJ, Timmann D.

Elife. 2019 Aug 29;8. pii: e46831. doi: 10.7554/eLife.46831.

3.

Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment.

Ziemann J, Lendeckel A, Müller S, Horneber M, Ritter CA.

Eur J Clin Pharmacol. 2019 Sep;75(9):1237-1248. doi: 10.1007/s00228-019-02700-6. Epub 2019 Jun 1.

PMID:
31154477
4.

General practitioner-pharmacist collaboration in Germany: an explanatory model.

Dähne A, Costa D, Krass I, Ritter CA.

Int J Clin Pharm. 2019 Aug;41(4):939-949. doi: 10.1007/s11096-019-00851-1. Epub 2019 May 28.

PMID:
31140161
5.

Process of translation and cross-cultural adaptation of two Australian instruments to evaluate the physician-pharmacist collaboration in Germany.

Weissenborn M, Krass I, Van C, Dähne A, Ritter CA, Haefeli WE, Seidling HM.

Res Social Adm Pharm. 2020 Jan;16(1):74-83. doi: 10.1016/j.sapharm.2019.03.009. Epub 2019 Mar 23.

PMID:
31122799
6.

Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients.

Marx S, Splittstöhser M, Kinnen F, Moritz E, Joseph C, Paul S, Paland H, Seifert C, Marx M, Böhm A, Schwedhelm E, Holzer K, Singer S, Ritter CA, Bien-Möller S, Schroeder HWS, Rauch BH.

Oncotarget. 2018 May 25;9(40):25860-25876. doi: 10.18632/oncotarget.25395. eCollection 2018 May 25.

7.

Validation of pharmacist-physician collaboration in psychiatry: 'the Eichberger-model'.

Hahn M, Ritter C, Roll SC.

Int J Clin Pharm. 2018 Oct;40(5):1001-1004. doi: 10.1007/s11096-018-0664-2. Epub 2018 May 23.

PMID:
29796963
8.

Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins.

Vogt K, Mahajan-Thakur S, Wolf R, Bröderdorf S, Vogel C, Böhm A, Ritter CA, Gräler M, Oswald S, Greinacher A, Kroemer HK, Jedlitschky G, Rauch BH.

Thromb Haemost. 2018 Jan;118(1):132-142. doi: 10.1160/TH17-04-0291. Epub 2018 Jan 5.

PMID:
29304533
9.

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.

Fischer T, Najjar A, Totzke F, Schächtele C, Sippl W, Ritter C, Hilgeroth A.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):1-8. doi: 10.1080/14756366.2017.1370583. Erratum in: J Enzyme Inhib Med Chem. 2018 Dec;33(1):433.

10.

Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.

Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde U, Frötschl R.

PLoS One. 2017 Jul 26;12(7):e0181081. doi: 10.1371/journal.pone.0181081. eCollection 2017.

11.

Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.

Fischer T, Krüger T, Najjar A, Totzke F, Schächtele C, Sippl W, Ritter C, Hilgeroth A.

Bioorg Med Chem Lett. 2017 Jun 15;27(12):2708-2712. doi: 10.1016/j.bmcl.2017.04.053. Epub 2017 Apr 19.

PMID:
28478927
12.

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R.

Hempel C, Totzke F, Schächtele C, Najjar A, Sippl W, Ritter C, Hilgeroth A.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):271-276. doi: 10.1080/14756366.2016.1247062.

13.

Systems pharmacology in drug development and therapeutic use - A forthcoming paradigm shift.

Kloft C, Trame MN, Ritter CA.

Eur J Pharm Sci. 2016 Oct 30;94:1-3. doi: 10.1016/j.ejps.2016.07.014. Epub 2016 Jul 21. No abstract available.

PMID:
27449395
14.

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.

Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, Fritah S, Harter PN, Välk K, Al Hossain J, Joseph JV, Jahedi R, Saed HS, Piccirillo SG, Spiteri I, Leiss L, Euskirchen P, Graziani G, Daubon T, Lund-Johansen M, Enger PØ, Winkler F, Ritter CA, Niclou SP, Watts C, Bjerkvig R, Miletic H.

Neuro Oncol. 2016 Dec;18(12):1644-1655. Epub 2016 Jun 10. Erratum in: Neuro Oncol. 2016 Dec;18(12 ):e2.

15.

Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer - Proof of concept towards a systems pharmacology approach.

Saafan H, Foerster S, Parra-Guillen ZP, Hammer E, Michaelis M, Cinatl J Jr, Völker U, Fröhlich H, Kloft C, Ritter CA.

Eur J Pharm Sci. 2016 Oct 30;94:20-32. doi: 10.1016/j.ejps.2016.04.025. Epub 2016 Apr 23.

PMID:
27112992
16.

Novel 4-anilino-α-carboline derivatives induce cell death in nonadhesive breast cancer cells through inhibition of Brk activity.

Oelze M, Mahmoud KA, Sippl W, Wersig T, Hilgeroth A, Ritter CA.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1052-5. doi: 10.5414/CPXCES14EA07. No abstract available.

PMID:
26396134
17.

Neural underpinnings of nocebo hyperalgesia in visceral pain: A fMRI study in healthy volunteers.

Schmid J, Bingel U, Ritter C, Benson S, Schedlowski M, Gramsch C, Forsting M, Elsenbruch S.

Neuroimage. 2015 Oct 15;120:114-22. doi: 10.1016/j.neuroimage.2015.06.060. Epub 2015 Jun 26.

PMID:
26123378
18.

The effect of treatment history on therapeutic outcome: psychological and neurobiological underpinnings.

Kessner S, Forkmann K, Ritter C, Wiech K, Ploner M, Bingel U.

PLoS One. 2014 Oct 2;9(9):e109014. doi: 10.1371/journal.pone.0109014. eCollection 2014.

19.

Immediate and transient phosphorylation of the heat shock protein 27 initiates chemoresistance in prostate cancer cells.

Stope MB, Weiss M, Preuss M, Streitbörger A, Ritter CA, Zimmermann U, Walther R, Burchardt M.

Oncol Rep. 2014 Dec;32(6):2380-6. doi: 10.3892/or.2014.3492. Epub 2014 Sep 17.

PMID:
25231055
20.

Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Herzog S, Fink MA, Weitmann K, Friedel C, Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, Miletic H, Hildner M, Fritsch M, Vogelgesang S, Havemann C, Ritter CA, Meyer zu Schwabedissen HE, Rauch B, Hoffmann W, Kroemer HK, Schroeder H, Bien-Möller S.

Neuro Oncol. 2015 Feb;17(2):223-42. doi: 10.1093/neuonc/nou216. Epub 2014 Aug 25.

Supplemental Content

Loading ...
Support Center